Regeneron (REGN) traded up 0.33 % during a 24 hours period ending at 10:15 PM Central Europe on Tuesday 27th. One Regeneron stock can currently be bought for about USD 816.1 on popular exchanges. Current supply of Regeneron stocks is 100 mn. Regeneron has a current market capitalization of USD 81.1 bn and approximately USD 342.4 mn worth of Regeneron was traded on exchanges in the last 24 hours. Since last month end, Regeneron has traded 7.37 % up. Simple moving average of last 200 days is at USD 736.04. The highest price of past 52 weeks was recorded at USD 859.34 on 09/03/2026. 52 weeks low was at USD 591.52 on 06/02/2026.
Summary of the latest news for Regeneron
Regeneron Pharmaceuticals has announced the extension of its agreement with the U.S. Biomedical Advanced Research and Development Authority to supply additional doses of its approved Ebola treatment, Inmazeb, through 2031. The expanded arrangement is expected to bring in approximately $270 million in payments and will continue to support U.S. preparedness for future Ebola outbreaks. Inmazeb, a combination of three monoclonal antibodies, has been used in hundreds of patients since 2019 and has demonstrated a significant mortality reduction in patients with low viral loads. Regeneron also indicated ongoing development of maftivimab, a component of Inmazeb, as a potential therapy for Ebola caused by the Bundibugyo virus, which is currently linked to the outbreak in the Democratic Republic of the Congo. The extension maintains the partnership that began with the initial procurement of Inmazeb in 2020 and underscores Regeneron’s continued role in public‑health emergency response.
Here is how related stocks have performed in the past 24 hours:
Monster Beverage (MNST) traded up 0.54 % and now trades at USD 45.44. Current market capitalisation for Monster Beverage is USD 90.4 bn. Monster Beverage has a current price to earnings ratio of 42.84.
Waste Management (WM) traded up 0.69 % and now trades at USD 235.81. Waste Management has a market capitalisation of USD 95.9 bn. Current price/earnings ratio for Waste Management is 33.77.
Us (USB) traded up 0.2 % and now trades at USD 59.74. Current market capitalisation for Us is USD 93.9 bn. Current price/earnings ratio for Us is 11.6. US Bancorp’s stock has shown a notable rise over the past year. Shares that traded at a closing price of 48.26 USD a year ago would now be valued around 59.58 USD, reflecting an increase in the company’s market capitalization to roughly 92.65 billion USD. Investors who had purchased the stock a year earlier would see their holdings appreciate, with the number of shares held growing from an initial 10,000 USD worth to more than double that amount. The company’s performance has been highlighted by a steady upward movement in share price, and the latest market cap figure indicates continued investor confidence. No adjustments for splits or dividends were included in these figures.
Intercontinental Exchange (ICE) traded down -1.65 % and now trades at USD 155.44. Current market capitalisation for Intercontinental Exchange is USD 90.9 bn. Current price/earnings ratio for Intercontinental Exchange is 23.03.
Elevance Health (ELV) traded down -1.96 % and now trades at USD 421.49. Elevance Health has a market capitalisation of USD 94.8 bn. Current price/earnings ratio for Elevance Health is 18.83. ELEVANCE HEALTH INC reported that it has concluded the sale of its interests in a lithium development project in Ghana to a Chinese cobalt producer. The transaction, completed after receiving the necessary governmental approvals, transferred all project rights, including the spodumene concentrate offtake agreement, to the buyer. As a result, the company no longer bears any funding obligations for the project. The proceeds from the sale are intended to enhance the firm’s financial flexibility and allow it to concentrate on its core North American lithium operations, including expansion of existing assets and other growth initiatives. The sale is independent of the buyer’s ongoing negotiations with a separate private‑sector stakeholder in the same project.
About Regeneron
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company based in Tarrytown, United States. The company specializes in discovering, developing, and commercializing pharmaceutical products for the treatment of serious medical conditions. As a part of the health care sector in the United States, Regeneron Pharmaceuticals primarily serves the biotechnology industry. The official website of the company is accessible under www.regeneron.com and its stock is traded on the Nasdaq stock exchange. The Initial Public Offering (IPO) of the company took place on April 2nd, 1991.